NASDAQ:BBTX Bambusa Therapeutics (BBTX) Stock Price, News & Analysis $16.00 +0.45 (+2.89%) As of 11/20/2026 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartInsider TradesSEC Filings About Bambusa Therapeutics Stock (NASDAQ:BBTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bambusa Therapeutics alerts:Sign Up Key Stats Today's Range$15.21▼$16.6950-Day Range N/A52-Week Range$13.60▼$17.65Volume137,667 shsAverage Volume374,353 shsMarket Capitalization$815.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation and fundamentally improve patient quality of life. Its pipeline includes BBT001, BBT002, BBT003 and BBT004. Bambusa Therapeutics, Inc. is based in BOSTON. Read More Receive BBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bambusa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBTX Stock News HeadlinesWall Street Zen Upgrades Bambusa Therapeutics (NASDAQ:BBTX) to HoldNovember 21 at 4:07 AM | americanbankingnews.comBambusa Therapeutics: Compelling Early Data Doesn't Justify The Current PremiumNovember 20 at 7:42 AM | seekingalpha.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 22 at 1:00 AM | Weiss Ratings (Ad)Bambusa Therapeutics (NASDAQ:BBTX) Director Ra Capital Management, L.P. Buys 453,820 Shares of StockNovember 4, 2026 | insidertrades.comBambusa Therapeutics (NASDAQ:BBTX) Stock: Insider Helmut Wolfgang Jeggle Purchases 375,000 SharesNovember 3, 2026 | insidertrades.comSee More Headlines BBTX Stock Analysis - Frequently Asked Questions How have BBTX shares performed this year? Bambusa Therapeutics' stock was trading at $14.99 on October 30, 2026. Since then, BBTX stock has increased by 6.7% and is now trading at $16.00. When did Bambusa Therapeutics IPO? Bambusa Therapeutics (BBTX) raised $169 million in an initial public offering on Friday, October 30th 2026. The company issued 10,555,555 shares at a price of $15.00-$17.00 per share. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor acted as the underwriters for the IPO. When does Bambusa Therapeutics' quiet period expire? Bambusa Therapeutics's quiet period expires on Wednesday, December 9th. Bambusa Therapeutics had issued 10,555,555 shares in its public offering on October 30th. The total size of the offering was $168,888,880 based on an initial share price of $16.00. During Bambusa Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. How do I buy shares of Bambusa Therapeutics? Shares of BBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:BBTX CIK2044950 Webwww.bambusatx.com Phone(949) 887-7927FaxN/AEmployees26Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares50,940,000Free FloatN/AMarket Cap$815.04 million OptionableN/A BetaN/A 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:BBTX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bambusa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bambusa Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.